MARKET

MGNX

MGNX

MacroGenics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.45
-0.85
-3.99%
After Hours: 21.10 +0.65 +3.18% 18:17 10/28 EDT
OPEN
20.72
PREV CLOSE
21.30
HIGH
20.96
LOW
20.30
VOLUME
569.64K
TURNOVER
--
52 WEEK HIGH
32.18
52 WEEK LOW
4.040
MARKET CAP
1.11B
P/E (TTM)
-6.0439
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for
MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 13h ago
Jazz Announces Topline Data, And Other News: The Good, Bad And Ugly Of Biopharma
Jazz Pharmaceuticals announces topline data from Phase 3 Xywav trial.MacroGenics reports positive data for flotetuzumab immunotherapy.Merck provides updated positive data for Keytruda in lung cancer.
Seekingalpha · 10/20 17:13
Macrogenics Entered Into Commercial Supply Agreement With Incyte On Oct. 13
-Reuters
Reuters · 10/16 13:37
MacroGenics reports that AML patients benefit from flotetuzumab immunotherapy
MacroGenics (MGNX) publishes a report on the role of Flotetuzumab (also known as MGD006) in the immunotherapy of TP53-positive acute myeloid leukemia ((AML)) in a journal of the American Society of Hematology.Flotetuzumab is an
Seekingalpha · 10/16 12:33
MacroGeneics Announces Flotetuzumab Publication In Blood Advances
MacroGenics Announces Flotetuzumab Publication in Blood Advances ROCKVILLE, MD, Oct. 15, 2020 (GLOBE NEWSWIRE) --   MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on
Benzinga · 10/15 20:33
Morgan Stanley Maintains Underweight on Macrogenics, Raises Price Target to $13
Morgan Stanley maintains Macrogenics (NASDAQ:MGNX) with a Underweight and raises the price target from $12 to $13.
Benzinga · 10/13 14:10
Zai Lab commences study in China testing margetuximab in stomach cancer
The first patient has been dosed in a China-based Phase 2/3 study, MAHOGANY, evaluating Zai Lab's (ZLAB) margetuximab, combined with a checkpoint inhibitor, with or without chemo, for the first-line
Seekingalpha · 10/06 12:01
Hedge Funds Are Coming Back To MacroGenics Inc (MGNX)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Insider Monkey · 10/05 16:19
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MGNX. Analyze the recent business situations of MacroGenics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MGNX stock price target is 29.40 with a high estimate of 40.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 202
Institutional Holdings: 61.66M
% Owned: 113.93%
Shares Outstanding: 54.12M
TypeInstitutionsShares
Increased
39
2.98M
New
63
9.49M
Decreased
45
5.86M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Director
Paulo Costa
President/Chief Executive Officer/Director
Scott Koenig
Chief Financial Officer/Senior Vice President/Secretary
James Karrels
Senior Vice President/Chief Scientific Officer
Ezio Bonvini
Senior Vice President
Stephen Eck
Senior Vice President
Eric Risser
Senior Vice President
Thomas Spitznagel
Vice President/General Counsel
Jeffrey Peters
Vice President/Controller/Treasurer
Lynn Cilinski
Independent Director
Karen Ferrante
Independent Director
Kenneth Galbraith
Independent Director
Edward Hurwitz
Independent Director
Scott Jackson
Independent Director
Jay Siegel
Independent Director
David Stump
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MGNX
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of MacroGenics Inc stock information, including NASDAQ:MGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MGNX stock methods without spending real money on the virtual paper trading platform.